Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Short Ideas
  • Short Sellers
  • Trading Ideas

Looking Into Alnylam Pharmaceuticals’s Recent Short Interest

By Benzinga Insights
Today, 3:42 PM
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all regular shares that are available for trading.

ALNY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $291

By Benzinga Newsdesk
Today, 3:42 PM
Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $310 to $291.

ALNY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

EF Hutton Reiterates Buy on Alnylam Pharmaceuticals, Maintains $304 Price Target

By Benzinga Newsdesk
Today, 3:42 PM
EF Hutton analyst Michael King reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $304 price target.

ALNY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $240 Price Target

By Benzinga Newsdesk
Today, 3:42 PM
Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $240 price target.

ALNY

Read More
17 minute read
  • Earnings

Earnings Scheduled For February 23, 2023

By Benzinga Insights
Today, 3:42 PM
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

AAOI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Lowers Price Target to $143

By Benzinga Newsdesk
Today, 3:42 PM
SVB Leerink analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and lowers the price target from $144 to $143.

ALNY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Piper Sandler Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $253

By Benzinga Newsdesk
Today, 3:42 PM
Piper Sandler analyst Edward Tenthoff maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $226 to $253.

ALNY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $145

By Benzinga Newsdesk
Today, 3:42 PM
SVB Leerink analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and raises the price target from $142 to $145.

ALNY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $236

By Benzinga Newsdesk
Today, 3:42 PM
Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $240 to $236.

ALNY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Goldman Sachs Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $270

By Benzinga Newsdesk
Today, 3:42 PM
Goldman Sachs analyst Salveen Richter maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $239 to $270.

ALNY

Posts navigation

1 2 … 15 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service